Efficacy and safety of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: A systematic review and meta-analysis

T-DXd has significant long-term and near-term efficacy in prolonging median overall survival, median PFS, and increasing the objective remission rate in patients with HER2-positive or low-expression breast cancer; however, the treatment is associated with notable adverse events, and physicians should be alert to the occurrence of serious adverse events when using this drug.